SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competitive concerns following Amazon Pharmacy's direct offering of Novo Nordisk's GLP-1 weight loss pill, which many in the community view as a significant headwind. While a vocal bearish contingent cites overvaluation and predicts further downside, a segment of investors sees current price levels as a strong buying opportunity, banking on the company's diversified telehealth platform and international expansion. The market is actively debating HIMS's growth trajectory and valuation as it navigates this evolving competitive landscape.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing extreme volatility and massive gains, largely fueled by a significant special cash dividend and discussions around a potential pivot to blockchain-based assets. The community is intensely focused on short squeeze potential and the dividend's impact, though many debate the company's underlying fundamentals against the backdrop of its dramatic price movements.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with investors expressing a mix of frustration over recent stock performance and renewed optimism for Briumvi's competitive standing. The community is actively discussing a competitor's recent regulatory setback, which highlights Briumvi's favorable profile, while anticipating potential strategic updates from the upcoming J.P. Morgan Healthcare Conference.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is experiencing significant buzz following a substantial stock and warrant offering to an institutional investor, priced notably above recent trading levels. This move signals strong institutional confidence in the company's future growth, particularly within the burgeoning autonomous drone and defense technology sector. While some debate potential dilution, many in the community are bullish, anticipating major acquisitions and contracts, especially with an investor conference approaching and heightened global defense spending.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amid intense buyout speculation, fueled by strong financial performance and anticipation of critical updates on its AUR200 pipeline, particularly regarding planned Phase 2 indications. Community discussion highlights growing frustration with management's perceived lack of transparency, even as the company's strong fundamentals and recent patent lawsuit consolidation position it as a compelling acquisition target in a dynamic biotech M&A environment.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is currently trending with significant community discussion around its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap. Despite a recent delisting, strong bullish sentiment persists due to its perceived low market cap and continued presence on major exchanges, with many anticipating substantial upside as a liquid staking protocol.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid significant price volatility, as recent strong earnings were followed by a sharp decline, attributed by some to institutional profit-taking and an analyst downgrade. The community is actively discussing heightened competition in the observability sector, particularly from a rival's rumored acquisition, while also seeing the current levels as a compelling buying opportunity given Datadog's robust AI integrations and sticky revenue. Adding to the buzz, there are circulating rumors about Datadog itself exploring a potential takeover bid for GitLab.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending due to a significant agreement with Meta Platforms to develop a nuclear energy campus in Ohio, aimed at powering future AI data centers. This deal, alongside anticipated DOE support for fuel and recent discussions on nuclear energy, has fueled intense bullish sentiment regarding the future of small modular reactors for AI infrastructure, despite some community concerns over current revenue and regulatory timelines.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is rallying due to significant regulatory clarity, as the FDA has confirmed a path for sonelokimab's Biologics License Application across key inflammatory skin disease indications without requiring additional pivotal trials. The community views this as a major de-risking event, fueling strong speculation around the drug's "best-in-class" potential, substantial upside, and renewed buyout interest from major pharmaceutical players.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending following recent strategic financing that has extended its cash runway toward crucial Phase 3 myelofibrosis trial results anticipated in March 2026. This development, coupled with bullish options activity, sparks optimism, yet a significant portion of the community remains vocal about perceived management shortcomings, believing a leadership change would be the strongest catalyst for unlocking the drug's full potential within the oncology sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SPYI $QQQI $IYRI $SPYH $QQQH 
 NEOS Investments Monthly Income Podcast (4/22/25) 
https://www.etftrends.com/monthly-income-channel/neos-podcast-harnessing-volatility-tax-efficient-income/